Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Clin Psychopharmacol ; 34(5): 577-87, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25006813

RESUMO

This study aimed to investigate the overall prescription pattern for patients with bipolar disorders in Korea and its relevance to the practice guidelines. Prescription records from all patients with bipolar I and II disorders who have been admitted or who started the outpatient treatment during the year of 2009 in 10 academic setting hospitals were reviewed. A total of 1447 patients with bipolar I and II disorders were included in this study. Longitudinal prescription patterns of inpatients and outpatients were analyzed by episode types and compared with the clinical practice guideline algorithms. In all phases, polypharmacy was chosen as an initial treatment strategy (>80%). The combination of mood stabilizer and atypical antipsychotics was the most favored. Antipsychotics were prescribed in more than 80% of subjects across all phases. The rate of antidepressant use ranged from 15% to 40%, and it was more frequently used in acute treatment and bipolar II subjects. The concordance rate of prescriptions for manic inpatients to the guidelines was higher and relatively more consistent (43.8%-48.7%) compared with that for depressive inpatients (18.6%-46.9%). Polypharmacy was the most common reason for nonconcordance. In Korean psychiatric academic setting, polypharmacy and atypical antipsychotics were prominently favored in the treatment of bipolar disorder, even with the lack of evidence of its superiority. More evidence is needed to establish suitable treatment strategies. In particular, the treatment strategy for acute bipolar depression awaits more consensuses.


Assuntos
Transtorno Bipolar/tratamento farmacológico , Quimioterapia Combinada/estatística & dados numéricos , Fidelidade a Diretrizes , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/estatística & dados numéricos , Adulto , Antidepressivos/uso terapêutico , Antipsicóticos/uso terapêutico , Feminino , Humanos , Masculino , República da Coreia/epidemiologia
2.
Immunol Lett ; 149(1-2): 110-8, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23018032

RESUMO

UVB irradiation can induce biological changes in the skin, modulate immune responses and activate inflammatory reactions leading to skin damage. Alloferon, which is isolated from the blood of an experimentally infected insect, the blow fly Calliphora vicina, is known for its anti-viral and anti-tumor activities in mice model. However, the effect of alloferon against UVB irradiation and its specific mechanism are still unknown. In this study, we investigated the effect of alloferon on UVB-induced cutaneous inflammation in a human keratinocyte cell line, HaCaT. RPA and ELISA data showed that alloferon decreased the production of UVB-induced pro-inflammatory cytokines, such as IL-1α, IL-1ß, IL-6 and IL-18, both on the mRNA and protein level. Western blot analysis was done to determine if alloferon regulates the MAPK signaling pathway since the MAPK signaling pathway is activated by numerous inflammatory mediators and environmental stresses including UVB irradiation. Alloferon inhibited the activation of p38 mitogen-activated protein kinase (MAPK) induced by UVB irradiation. Furthermore, the topical application of alloferon on the UVB exposed skin of hairless mice showed that alloferon treatment significantly inhibited an increase in epithelial thickness in chronic UVB-irradiated mouse skin. These findings suggest that alloferon has significant anti-inflammatory effects not only on UVB-induced inflammation in the human keratinocyte cell line, HaCaT, but also on mouse skin.


Assuntos
Citocinas/imunologia , Dermatite/imunologia , Regulação para Baixo/efeitos dos fármacos , Mediadores da Inflamação/imunologia , Peptídeos/farmacologia , Pele/imunologia , Raios Ultravioleta/efeitos adversos , Animais , Antineoplásicos/farmacologia , Antivirais/farmacologia , Linhagem Celular , Citocinas/biossíntese , Dermatite/tratamento farmacológico , Dermatite/metabolismo , Dermatite/patologia , Regulação para Baixo/imunologia , Regulação para Baixo/efeitos da radiação , Humanos , Mediadores da Inflamação/metabolismo , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Sistema de Sinalização das MAP Quinases/imunologia , Sistema de Sinalização das MAP Quinases/efeitos da radiação , RNA Mensageiro/biossíntese , RNA Mensageiro/imunologia , Pele/metabolismo , Pele/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA